# US 2026/0077040 A1 · Compositions and methods for treating advanced solid tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077040 A1
- Document ID: US20260077040A1
- Status: Published application
- Kind: A1
- Application number: 19/108,552
- Filed: 2023-09-08
- Published: 2026-03-19
- Earliest claimed: 2022-09-09
- Applicants: Astrazeneca AB
- Inventors: Haiyi JIANG
- Web page: https://patentgrep.com/patent/US20260077040A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/243: Platinum; Compounds thereof
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/585: {wherein the target is cancer}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Disclosed are methods for treating solid tumors with an anti-PD-L1 antibody and an anti-CTLA-4 antibody concurrently with chemoradiation therapy (cCRT).

## Claims

### Claim 1

A method of increasing the overall response rate (ORR) or disease control rate (DCR) in a patient with small-cell lung cancer (SCLC), the method comprising concurrently treating the patient with a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and chemoradiation therapy.

### Claim 2

(canceled)

### Claim 3

A method of treating a patient with SCLC, the method comprising concurrently treating the patient with a human anti-PD-L1 antibody, an anti-CTLA-4 antibody, and chemoradiation therapy.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the SCLC is limited stage.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the chemoradiation therapy comprises 60 to 70 Gy in 30 to 35 fractions.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the chemoradiation therapy comprises 2 Gy/fraction, 5 fractions per week, over 6 to 7 weeks.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the chemoradiation therapy comprises hyperfractionated radiation.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the hyperfractionated radiation comprises 45 Gy in 30 fractions.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the hyperfractionated radiation comprises 1.5 Gy/fractions, 2 fractions per day at least 6 hours apart, 10 fractions per week, over 3 weeks.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the chemoradiation therapy comprises cisplatin and/or carboplatin and etoposide.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the anti-CTLA-4 antibody is tremelimumab.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.

### Claim 13 (depends on 1)

The method according to claim 1, wherein treatment with the human anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).

### Claim 14 (depends on 1)

The method according to claim 1, wherein treatment with the anti-CTLA-4 antibody comprises administering 75 mg of the anti-CTLA-4 antibody to the patient intravenously every four weeks (Q4W).

### Claim 15 (depends on 1)

The method according to claim 1, wherein the anti-PD-L1 antibody and the anti-CTLA-4 antibody are administered on the first day of chemoradiation therapy.

### Claim 16

A method of increasing the overall response rate (ORR) or disease control rate (DCR) in a patient with squamous cell carcinoma of the head and neck (HNSCC), the method comprising concurrently treating the patient with a human anti-PD-L1 antibody and chemoradiation therapy.

### Claim at position 17

17-56. (canceled)
